



February 18, 2016

Celldex to Report Fourth Quarter and Year-End 2015 Business/Financial Results and Host 2016 Corporate Strategy Conference Call

--Conference Call Scheduled for Thursday, February 25 at 8:00 a.m. Eastern Time--

HAMPTON, N.J., Feb. 18, 2016 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will release fourth quarter and year-end 2015 financial results on Thursday, February 25, 2016 before the U.S. financial markets open. Celldex executives will host a conference call at 8:00 a.m. EST on the same day to discuss 2015 financial and business results and to provide an update on key 2016 objectives.

The conference call and presentation will be webcast live over the Internet and can be accessed by going to the "Events & Presentations" page under the "Investors & Media" section of the Celldex Therapeutics website at www.celldex.com. The call can also be accessed by dialing (866) 743-9666 (within the United States) or (760) 298-5103 (outside the United States). The passcode is 50465153.

A replay of the call will be available approximately two hours after the live call concludes through March 3, 2016. To access the replay, dial (855) 859-2056 (within the United States) or (404) 537-3406 (outside the United States). The passcode is 50465153. The webcast will also be archived on the Company's website.

About Celldex Therapeutics, Inc.

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Visit www.celldex.com.

Contact

Sarah Cavanaugh

Vice President of Investor Relations & Corp Communications

Celldex Therapeutics, Inc.

(781) 433-3161

scavanaugh@celldex.com

Charles Liles

Manager of Investor Relations & Corp Communications

Celldex Therapeutics, Inc.

(781) 433-3107

cliles@celldex.com

 Primary Logo

Source: Celldex Therapeutics, Inc.

